Test Price
2,800 AED✅ Home Collection Available
DES Gene Myofibrillar Myopathy (Desmin‑Related) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – ISO‑Certified for Blood, Extracted DNA, or FTA Card.
Clinical Guidance
Telephonic Post‑Test Clinical Guidance with Result Interpretation by DHA‑Licensed Specialists.
Insurance
Direct Billing Verification via WhatsApp +971 54 548 8731 (Pre‑approval support).
Test Overview & Methodology
This test sequences the entire DES gene using next‑generation sequencing (NGS) with copy number variation analysis, confirming or ruling out desmin‑related myofibrillar myopathy. It is the most precise non‑invasive genetic diagnostic tool for patients with progressive muscle weakness and suspected desminopathy. The assay employs Illumina NovaSeq chemistry with MLPA verification for CNV detection, achieving 99.9% diagnostic sensitivity. A concise narrative of the patient’s neuromuscular symptoms, age of onset, and any echocardiogram results must accompany the test requisition. Mandatory pre‑test genetic counselling by a DHA‑licensed genetic counsellor completes a three‑generation pedigree before specimen collection, ensuring informed consent compliance under Federal Decree‑Law No. 4 of 2016 on Medical Liability.
| Feature | Our Test (NGS + CNV) | Muscle Biopsy with IF |
|---|---|---|
| Precision | 99.9% sensitivity, full‑gene & CNV | ~80–90% sensitivity, limited to protein expression |
| Method | Illumina NovaSeq NGS with MLPA verification | Invasive surgical biopsy + immunohistochemistry |
| Turnaround | 3–4 weeks | 4–8 weeks (including histopathology) |
| Cost | 2800 AED | 6000–8000 AED |
| Sample | Blood, Extracted DNA, or FTA Card | Fresh muscle tissue (open biopsy) |
Physician Insight & Safety Protocols
“Pursuing a genetic diagnosis for a progressive neuromuscular condition requires thoughtful preparation and support. This assay provides definitive molecular evidence that directly informs prognosis, cardiac surveillance intervals, and cascade screening for at‑risk family members. I am committed to guiding patients through each step from pre‑test counselling to post‑result care planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This test does not replace ongoing neurological or cardiac management. Always discuss genetic results with your treating specialist before making any therapeutic changes.
Exclusion Criteria & Emergency Red Flags
- Inability to provide informed consent (severe psychiatric illness, cognitive impairment without legal guardian) in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Active systemic infection that prevents safe venipuncture.
- Children under 18 years without a legally authorized guardian’s consent, per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Seek emergency care if you experience:
- New‑onset chest pain, palpitations, or fainting
- Rapidly worsening limb weakness or breathing difficulty
- Unexplained collapse or loss of consciousness
Patient FAQ & Clinical Guidance
1. What is the DES gene myofibrillar myopathy genetic test?
This genetic test identifies DES mutations causing myofibrillar myopathy, a progressive muscle and cardiac disorder. It reads the full coding sequence and adjacent intronic boundaries of the desmin gene using next‑generation sequencing (NGS). Because desminopathies may present with cardiomyopathy, a positive result prompts immediate cardiology evaluation. Results are interpreted by a board‑certified clinical geneticist and neurologist to ensure accurate phenotype correlation.
2. Why is this genetic test recommended for me or my family?
A positive result confirms a definitive molecular diagnosis, guiding treatment, cardiac monitoring, and family screening decisions. DES‑related myofibrillar myopathy is inherited in an autosomal dominant pattern; thus, first‑degree relatives have a 50% risk. Predictive testing in asymptomatic adults clarifies their future health surveillance needs. Genetic counselling, included in our pre‑test protocol, draws a detailed pedigree to assess at‑risk relatives.
3. How do I prepare for the DES gene test and receive my results?
No fasting is required; a simple blood draw or FTA card sample collected at home initiates the process. A mandatory genetic counselling session conducted by our DHA‑licensed team will document your family pedigree before the sample is processed. Results are ready in 3–4 weeks and are released only via a tele‑consultation with a neurologist or genetic counsellor to ensure safe result interpretation. Direct insurance billing and home phlebotomy can be arranged through WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
- ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) – Medical Testing & Genetic Services.
- Full alignment with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – all genetic data is encrypted, stored locally, and accessible only to authorized clinical personnel.
- Strict adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health data handling and tele‑consultation frameworks.
- Informed consent and clinical safety protocols comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- DHA Facility License Number: 1143.
Clinical & Logistical Metadata
| Test Name | DES Gene Myofibrillar Myopathy (Desmin‑Related) Genetic Test – Full Gene Sequencing with CNV Analysis |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from receipt of properly collected sample and completed pedigree |
| Sample Type / Matrix | Whole blood (EDTA tube, 2–5 mL), Extracted DNA (≥1 µg, concentration ≥25 ng/µL), or Dried Blood Spot on FTA Card (≥3 circles). VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM. |
| Methodology Used | Next‑Generation Sequencing (Illumina NovaSeq) with Copy Number Variation analysis via MLPA and bioinformatic pipeline |
| ICD-10-CM Code | G71.8 – Other primary disorders of muscles (Myofibrillar myopathy); Z15.09 – Genetic susceptibility to other disease; I42.9 – Cardiomyopathy, unspecified (if cardiac phenotype) |
| LOINC Code | 101031-5 – DES gene full mutation analysis in Blood or Tissue by Molecular genetics method |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians